# Intuitive Ventures

> Intuitive Ventures is a VC fund backing Health Care and Medical Device. See 23 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Sunnyvale, United States
- Total investments: 23
- Last investment: Jan 2026
- Lead investor: 22%
- Fund size: $100M
- Last fund: Oct 2020
- Last updated: Aug 2026
- Website: https://ventures.intuitive.com/

Intuitive Ventures is a VC fund in Sunnyvale focused on Health Care and Medical Device. Intuitive Ventures focuses on early-stage start-ups and takes a long-term outlook to support companies to reach their major milestones. Through its inaugural $100 million funds and with leadership combining decades of investing and operational experience, the team cultivates strategic resources to drive financial returns and accelerate the futureof minimally invasive care. Intuitive Ventures has already started deploying capital and is actively building its portfolio.

## Contacts

5 contacts available for Intuitive Ventures. Shizune tracks 1 team members at Intuitive Ventures. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/intuitive-ventures?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 9 | 39% |
| Medical Device | 9 | 39% |
| Medical | 4 | 17% |
| Software | 4 | 17% |
| Therapeutics | 3 | 13% |

22 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 7 | 30% |
| Series A | 5 | 22% |
| Series C | 3 | 13% |
| Series D | 3 | 13% |
| Venture - Series Unknown | 2 | 9% |

7 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 13 | 57% |
| United Kingdom | 3 | 13% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Julian Nikolchev | Sr VP Corprate Development & Strategy; President, Intuitive Ventures, | 0 | — |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Cellares | Cellares develops and operates integrated technologies for automated cell therapy manufacturing and quality control that help biopharmaceutical partners scale development to industrial production. The company’s offerings include the Cell Shuttle platform for end-to-end automation of the cell therapy manufacturing process and the Cell Q platform forautomated quality control, supported by integrated software and consumable cartridges. Cellares positions itself as an Integrated Development and Manufacturing Organization that supports process transfer, scalable production, and regulatory pathways for clinical and commercial programs. Its services enable clients to transition manual processes onto automated systems and expand manufacturing capacity to meet broader patient demand. | $257M | Series D | Jan 28, 2026 |  |
| VahatiCor | VahatiCor specializes in medical equipment manufacturing, focusing on solutions for coronary microvascular dysfunction. The company is known for its A-FLUX Reducer System, which addresses the complexities of ischemic heart disease and provides relief for patients experiencing angina and chest pain. VahatiCor aims to improve coronarymicrocirculatory function with its next-generation medical technologies. | $23M | Series B | Nov 18, 2025 |  |
| Sovato Health | Sovato Health provides surgical access through remote robotic surgeon options. | $41M | Series B | Nov 04, 2025 |  |
| Apreo Health | Apreo Health is developer of medical apparatus designed for diagnosing or treating respiratory, pulmonary, and lung conditions. | $130M | Series B | Aug 07, 2025 |  |
| OrganOx | OrganOx Limited was founded in 2008 to exploit normothermic preservation technology invented by Prof Peter Friend and colleagues and further developed by Prof Constantin Coussios at the University of Oxford. | $160M | Venture - Series Unknown | Feb 24, 2025 |  |
| Capstan Medical | Capstan Medical is creating minimally invasive technologies to treat heart valve disorders. | $110M | Series C | Dec 11, 2024 |  |
| XII Medical | XII Medical is a medical device developer company. It develops a minimally invasive outpatient technology for the treatment of obstructive sleep apnea. | $45M | Series B | Aug 21, 2024 |  |
| Endogenex | Endogenex develops an endoscopic procedure to help patients with type 2 diabetes regain control of their blood glucose levels. Established in 2017, Endogenex has developed a novel therapy that utilizes pulsed electric fields to promote regeneration of the duodenal mucosa for improvement in glycemic control in patients with T2D. | $88M | Series C | Jun 25, 2024 |  |
| Amber Therapeutics | Amber Therapeutics develops the next-generation of bioelectrical therapies that can sense and adapt as well as stimulate, with the potential to radically improve clinical outcomes in patients with functional disorders of the peripheral nervous system. | $101.8M | Series A | Jun 09, 2024 |  |
| Capstan Medical | Capstan Medical is creating minimally invasive technologies to treat heart valve disorders. | $31.4M | Series B | Aug 09, 2023 |  |

10 of 23 investments shown.

## Co-investors
- [8VC](https://shizune.co/investors/profile/8vc) — VC Fund, 5 deals together
- [Eclipse](https://shizune.co/investors/profile/eclipse-ventures) — VC Fund, 4 deals together
- [Sante Ventures](https://shizune.co/investors/profile/sante-ventures) — VC Fund, 4 deals together
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund, 3 deals together
- [Beringea](https://shizune.co/investors/profile/beringea) — VC Fund, 3 deals together
- [Norwest](https://shizune.co/investors/profile/norwest-venture-partners) — VC Fund, 3 deals together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Intuitive Ventures invest in?

Intuitive Ventures invests primarily in Health Care, Medical Device and Medical startups, most often at Series B and Series A stage. Most of the 23 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Intuitive Ventures?

Public channels for Intuitive Ventures include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Intuitive Ventures?

The team at Intuitive Ventures includes Julian Nikolchev (Sr VP Corprate Development & Strategy; President, Intuitive Ventures,). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co